---
id: aace-hypoparathyroidism-2025
title: "AACE 2025 International Consensus: Diagnosis and Management of Hypoparathyroidism"
short_title: "AACE Hypoparathyroidism 2025"

organization: American Association of Clinical Endocrinology
collaborators: null
country: Global (US-led)
url: https://www.aace.com/publications/clinical-guidance
doi: null
pmid: null
open_access: true

specialty: endocrinology
guideline_type: clinical-practice
evidence_system: AACE Consensus
conditions:
  - hypoparathyroidism
  - hypocalcemia
  - post-surgical hypocalcemia
tags:
  - calcium supplementation
  - vitamin D
  - PTH replacement
  - NATPARA
  - calcitriol

publication_date: 2025-03-01
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
2025 international consensus from AACE providing practical guidance for the diagnosis and management of hypoparathyroidism.

## Key Recommendations

### Diagnosis
- **Definition**: Chronic hypocalcemia in the setting of undetectable or inappropriately low PTH levels.
- **Most Common Cause**: Post-surgical (after thyroidectomy or parathyroidectomy).
- **Labs**: Low albumin-corrected calcium or ionized calcium, low or undetectable PTH, normal or high phosphorus, low 1,25(OH)â‚‚D.

### Symptoms
- Neuromuscular irritability (paresthesias, muscle cramps, tetany).
- Trousseau's and Chvostek's signs.
- Cognitive symptoms, fatigue, and QTc prolongation.

### Goals of Therapy
- Maintain serum calcium in the low-normal range (8.0-8.5 mg/dL) to avoid symptoms and prevent hypercalciuria.
- Avoid hypercalcemia and hypercalciuria (target 24-hour urine calcium <300 mg/day).
- Maintain serum phosphorus in the normal range.

### Conventional Therapy
- **Calcium Supplementation**: Calcium carbonate or citrate, typically 1.5-3 grams of elemental calcium/day in divided doses.
- **Active Vitamin D (Calcitriol)**: 0.25-2 mcg/day to enhance intestinal calcium absorption. Preferred over ergocalciferol or cholecalciferol.
- **Thiazide Diuretics**: May be added to reduce urinary calcium excretion.
- **Magnesium**: Correct hypomagnesemia if present, as it can impair PTH secretion and action.

### PTH Replacement Therapy
- **Recombinant PTH 1-84 (Natpara - availability varies)**: For patients inadequately controlled on conventional therapy (requiring high doses of calcium and active vitamin D, with hypercalciuria or renal complications).
- **TransCon PTH (Palopegteriparatide)**: A newer long-acting PTH prodrug.

### Monitoring
- Regular monitoring of serum calcium, phosphorus, magnesium, creatinine, and 24-hour urine calcium.
- Periodic renal imaging to monitor for nephrocalcinosis.
